On March 15, 2017, Tatiana Y. Lin, M.A., KHI Senior Analyst and Strategy Team Leader, provided neutral testimony on House Bill 2152 to the House Committee on Health and Human Services. The bill would, among other things, authorize hemp treatments for certain medical conditions.
During the testimony, KHI discussed findings and recommendations from its 2015 health impact assessment (HIA) Potential Health Effects of Legalizing Medical Marijuana in Kansas.
For more information, see the following documents:
Testimony: A Health Impact Assessment on Legalization of Medical Marijuana in Kansas
Executive Summary: Potential Health Effects of Legalizing Medical Marijuana in Kansas
Key Findings and Recommendations: Potential Health Effects of Legalizing Medical Marijuana in Kansas
Map: Medical Marijuana Laws in the United States (November 2016)
The Kansas Health Institute (KHI) delivers objective information, conducts credible research, and supports civil dialogue enabling policy leaders to make informed health policy decisions that enhance their effectiveness as champions for a healthier Kansas. Established in 1995 with a multiyear grant from the Kansas Health Foundation, KHI is a nonprofit, nonpartisan educational organization based in Topeka.